CA3150755A1 - Polymorphic forms of deoxycytidine, compositions comprising the same and uses - Google Patents
Polymorphic forms of deoxycytidine, compositions comprising the same and uses Download PDFInfo
- Publication number
- CA3150755A1 CA3150755A1 CA3150755A CA3150755A CA3150755A1 CA 3150755 A1 CA3150755 A1 CA 3150755A1 CA 3150755 A CA3150755 A CA 3150755A CA 3150755 A CA3150755 A CA 3150755A CA 3150755 A1 CA3150755 A1 CA 3150755A1
- Authority
- CA
- Canada
- Prior art keywords
- ppm
- deoxycytidine
- composition
- residual solvent
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962888893P | 2019-08-19 | 2019-08-19 | |
| US62/888,893 | 2019-08-19 | ||
| PCT/US2020/047047 WO2021034962A1 (en) | 2019-08-19 | 2020-08-19 | Polymorphic forms of deoxycytidine, compositions comprising the same and uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3150755A1 true CA3150755A1 (en) | 2021-02-25 |
Family
ID=74647126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3150755A Pending CA3150755A1 (en) | 2019-08-19 | 2020-08-19 | Polymorphic forms of deoxycytidine, compositions comprising the same and uses |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11649259B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4017502A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7769603B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN114929240B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2020334060B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022002513A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3150755A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021034962A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022204555A1 (en) * | 2021-03-26 | 2022-09-29 | Zogenix Mds, Inc. | Aqueous solutions containing purines and pyrimidines and uses thereof |
| WO2026082601A2 (en) * | 2024-10-15 | 2026-04-23 | UCB Biopharma SRL | Method of purification |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4898936A (en) * | 1984-09-24 | 1990-02-06 | Pcr, Inc. | 2-deoxyuridines and riboside precursors |
| JPS61135597A (ja) * | 1984-12-06 | 1986-06-23 | Takeda Chem Ind Ltd | シチジンおよびデオキシシチジンの製造法 |
| US4900828A (en) * | 1988-05-12 | 1990-02-13 | Hoffmann-Laroche Inc. | Intermediate compounds and an improved procedure for the synthesis of 2',3'-dideoxycytidine |
| JP2002255991A (ja) * | 2000-12-27 | 2002-09-11 | Mitsui Chemicals Inc | 保護化2’−デオキシシチジン誘導体の製造法 |
| JP2002293791A (ja) * | 2001-03-30 | 2002-10-09 | Mitsui Chemicals Inc | 保護化2’−デオキシシチジン誘導体の精製法 |
| CN100424091C (zh) * | 2002-06-05 | 2008-10-08 | 三井化学株式会社 | 保护化2’-脱氧胞苷类的精制法 |
| EP1551838B1 (en) * | 2002-10-16 | 2006-08-09 | Teva Pharmaceutical Industries Ltd. | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| US9669048B2 (en) * | 2012-10-25 | 2017-06-06 | Fresenius Kabi Oncology Limited | Stable pharmaceutical composition of 5-aza-2′-deoxycitidine |
| WO2016205671A1 (en) | 2015-06-17 | 2016-12-22 | The Trustees Of Columbia University In The City Of New York | Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes |
| GB2580963C (en) * | 2019-02-01 | 2025-09-03 | Hemispherian As | Cancer therapies |
-
2020
- 2020-08-19 EP EP20854948.5A patent/EP4017502A4/en active Pending
- 2020-08-19 AU AU2020334060A patent/AU2020334060B2/en active Active
- 2020-08-19 BR BR112022002513A patent/BR112022002513A2/pt unknown
- 2020-08-19 US US16/997,727 patent/US11649259B2/en active Active
- 2020-08-19 JP JP2022510955A patent/JP7769603B2/ja active Active
- 2020-08-19 CN CN202080073216.4A patent/CN114929240B/zh active Active
- 2020-08-19 CA CA3150755A patent/CA3150755A1/en active Pending
- 2020-08-19 WO PCT/US2020/047047 patent/WO2021034962A1/en not_active Ceased
-
2025
- 2025-07-10 JP JP2025116467A patent/JP2025160233A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7769603B2 (ja) | 2025-11-13 |
| AU2020334060A1 (en) | 2022-03-24 |
| US20210054014A1 (en) | 2021-02-25 |
| EP4017502A4 (en) | 2023-11-01 |
| CN114929240A (zh) | 2022-08-19 |
| JP2025160233A (ja) | 2025-10-22 |
| EP4017502A1 (en) | 2022-06-29 |
| CN114929240B (zh) | 2024-10-29 |
| AU2020334060B2 (en) | 2024-11-14 |
| JP2022544831A (ja) | 2022-10-21 |
| US11649259B2 (en) | 2023-05-16 |
| BR112022002513A2 (pt) | 2022-05-03 |
| WO2021034962A1 (en) | 2021-02-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110636884B (zh) | 新结晶形式 | |
| TWI920053B (zh) | 2-[3-[4-胺基-3-(2-氟-4-苯氧基-苯基)-1H-吡唑并[3,4-d]嘧啶-1-基]哌啶-1-羰基]-4-甲基-4-[4-(氧環丁烷-3-基)哌-1-基]戊-2-烯腈之晶形 | |
| RU2414470C2 (ru) | Кристаллические формы соединения тиазолидиндиона и способ его получения | |
| CN102325778B (zh) | 盐酸纳美芬二水合物 | |
| JP2025160233A (ja) | デオキシシチジンの多形形態、それを含む組成物および使用 | |
| TW201136593A (en) | Nucleoside phosphoramidates | |
| KR102788829B1 (ko) | 야누스 키나제 억제제의 결정질 형태 | |
| US20230151048A1 (en) | Crystal form, preparation method, and application of 4′-substituted nucleoside | |
| US9085607B2 (en) | ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof | |
| AU2012228439C1 (en) | Pyridinyl- and pyrazinyl -methyloxy - aryl derivatives useful as inhibitors of spleen tyrosine kinase (SYK) | |
| CN116745292A (zh) | 经取代的吡啶并三嗪化合物及其用途 | |
| EP3650448A1 (en) | Indole-formamide derivative, preparation method therefor and use thereof in medicine | |
| KR20190022556A (ko) | 간 전송 항바이러스 전구체 약물 뉴클레오시드 시클로 포스페이트 에스테르 화합물 및 응용 | |
| KR102566383B1 (ko) | 3-하이드록시-비스-벤질옥시-6-벤질옥시메틸-2-페닐-2-옥소-2λ5-[1,2]옥사포스피난의 결정질 다형 형태 | |
| CN118005694B (zh) | 一种环状核苷类似物及其制备方法和应用 | |
| US20260091039A1 (en) | Hydrochloric acid salt of a 5-ht2c agonist | |
| WO2023105483A1 (en) | Crystalline forms of a 5-aminopyrazole compound useful for treating hbv | |
| CN113666895B (zh) | 卤代2-苯并[c]呋喃酮类化合物及其应用 | |
| CN116829153A (zh) | 治疗流感化合物的晶型及应用 | |
| KR20210155806A (ko) | Pi3k 저해제의 결정다형 및 이의 제조방법 | |
| WO2025032190A1 (en) | Crystalline form a1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hcl | |
| CN103237804B (zh) | 制备纳曲酮的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20241101 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241101 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20241121 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20241213 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241213 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R00-R125 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMMON REPRESENTATIVE APPOINTED Effective date: 20250307 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250307 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250411 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250430 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250811 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251211 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260120 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260120 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260120 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260701 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260702 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260728 |